EX-99.2 3 y13812exv99w2.txt CERTAIN SUPPLEMENTAL INFORMATION Exhibit 99.2 MERCK & CO., INC. OTHER FINANCIAL DISCLOSURES THIRD QUARTER 2005 NET PRODUCT SALES DETAIL (MILLIONS OF DOLLARS)
3Q `05 vs. 3Q `04 TOTAL TOTAL U.S. U.S. FOREIGN FOREIGN PRODUCT % CHG $ % CHG $ % CHG $ AGGRASTAT 7% 21 N/A - 7% 21 ARCOXIA -8% 56 N/A - -8% 56 CANCIDAS 31% 142 23% 80 43% 62 COZAAR / HYZAAR 6% 751 3% 268 8% 484 CRIXIVAN / STOCRIN 40% 91 9% 9 45% 82 EMEND 60% 22 46% 19 * 4 FOSAMAX - 777 4% 461 -5% 316 INVANZ 51% 25 39% 15 75% 9 MAXALT 10% 92 10% 62 11% 30 PRIMAXIN 12% 182 21% 51 9% 131 PROPECIA - 67 -12% 29 11% 38 PROSCAR 3% 186 8% 98 -1% 88 SINGULAIR 11% 692 10% 490 13% 203 TIMOPTIC / TIMOPTIC XE -9% 35 7% 2 -10% 32 TRUSOPT / COSOPT 13% 156 10% 66 16% 91 VASOTEC / VASERETIC -12% 149 N/A - -12% 149 VIOXX * - * - * - ZOCOR -14% 1,050 -10% 770 -24% 280 HEPATITIS VACCINES 34% 65 38% 55 25% 10 VIRAL VACCINES 11% 186 11% 171 15% 15 OTHER VACCINES 7% 88 9% 71 - 17
* 100% or over N/A - Not Applicable Total Sales: Volume, Price, Exchange
3Q `05 % Chg. Vol Px Fx TOTAL PHARMACEUTICAL SALES $ 5,416 -2% -4 1 1 ------- ----- ----- ----- ----- U.S. ($ MM) 3,232 -5% -7 3 N/A Foreign ($ MM) 2,184 2% - -1 2
Exhibit 99.2 MERCK & CO., INC. OTHER FINANCIAL DISCLOSURES SEPTEMBER YEAR-TO-DATE 2005 NET PRODUCT SALES DETAIL (MILLIONS OF DOLLARS)
SEPTEMBER YTD `05 vs. SEPTEMBER YTD `04 TOTAL TOTAL U.S. U.S. FOREIGN FOREIGN PRODUCT % CHG $ % CHG $ % CHG $ AGGRASTAT 6% 66 N/A - 6% 66 ARCOXIA 6% 163 N/A - 6% 163 CANCIDAS 39% 413 29% 222 52% 190 COZAAR / HYZAAR 9% 2,255 4% 762 13% 1,493 CRIXIVAN / STOCRIN 34% 258 41% 29 33% 229 EMEND * 59 88% 51 * 8 FOSAMAX 3% 2,402 2% 1,346 5% 1,056 INVANZ 51% 67 36% 42 88% 25 MAXALT 16% 254 19% 163 12% 92 PRIMAXIN 18% 548 45% 156 10% 392 PROPECIA 6% 206 -1% 93 12% 113 PROSCAR 2% 549 1% 271 3% 278 SINGULAIR 14% 2,157 11% 1,472 21% 685 TIMOPTIC / TIMOPTIC XE -10% 103 12% 8 -11% 95 TRUSOPT / COSOPT 12% 450 3% 175 18% 275 VASOTEC / VASERETIC -12% 471 N/A - -12% 471 VIOXX * - * - * - ZOCOR -15% 3,307 -14% 2,322 -16% 985 HEPATITIS VACCINES -3% 146 -10% 112 25% 34 VIRAL VACCINES 11% 463 9% 417 30% 47 OTHER VACCINES 11% 200 6% 147 29% 53
* 100% or over N/A - Not Applicable Total Sales: Volume, Price, Exchange
YTD `05 % CHG. VOL PX FX TOTAL PHARMACEUTICAL SALES $ 16,246 -5% -8 1 2 -------- --- --- -- --- U.S. ($ MM) 9,284 -8% -11 3 N/A Foreign ($ MM) 6,962 -2% -4 -2 4
Exhibit 99.2 MERCK & CO., INC. OTHER FINANCIAL DISCLOSURES THIRD QUARTER 2005 OTHER (INCOME)/EXPENSE, NET (MILLIONS OF DOLLARS)
3Q `05 3Q `04 YTD 2005 YTD 2004 INTEREST INCOME $ (122.3) $ (75.7) $ (314.8) $ (209.8) INTEREST EXPENSE 99.6 72.4 277.2 216.8 EXCHANGE (GAINS)/LOSSES (7.4) 2.8 (16.5) 9.9 MINORITY INTERESTS 30.9 37.6 91.6 114.0 Other, net (25.5) (41.3) (21.7) (370.9) ---------- -------- --------- --------- TOTAL $ (24.7) $ (4.2) $ 15.8 $ (240.0) ========== ======== ========= =========
================================================================================ JOINT VENTURE SALES DETAIL (MILLIONS OF DOLLARS) All sales reported here are JV sales, presented on a "NET" basis.
MERIAL 3Q `05 3Q `04 YTD 2005 YTD 2004 IVOMEC, HEARTGARD, other avermectins $ 124 $ 139 $ 350 $ 335 FRONTLINE 199 224 614 569 Biologicals 133 120 384 343 Other Animal Health 57 55 172 165 ------ -------- ------- --------- TOTAL MERIAL SALES $ 513 $ 538 $ 1,520 $ 1,412 ====== ======== ======= =========
SANOFI PASTEUR-MSD 3Q `05 3Q `04 YTD 2005 YTD 2004 HEPATITIS VACCINES $ 21 $ 20 $ 66 $ 61 VIRAL VACCINES 22 15 61 42 Other Vaccines 256 239 539 483 ------ -------- ------- --------- TOTAL SANOFI-MSD SALES $ 300 $ 274 $ 666 $ 586 ====== ======== ======= =========
MERCK / SCHERING-PLOUGH COLLABORATION 3Q `05 3Q `04 YTD 2005 YTD 2004 VYTORIN (Worldwide) $ 274 $ 52 $ 673 $ 56 ZETIA (Worldwide) 356 293 1,005 725 ------ -------- ------- --------- TOTAL $ 630 $ 345 $ 1,679 $ 781 ====== ======== ======= =========
================================================================================